Resources

Please see the resources below to learn more about the issues surrounding the use of biosimilars. 

Letters

December 18, 2014

Follow-up Biologics Prescribers Letter to FDA on Distinguishable Naming

On December 18, the Biologics Prescribers Collaborative sent a second letter to FDA Commissioner Hamburg advocating for distinguishable naming for biosimilars. Read More ›

August 14, 2014

Biologics Prescribers Letter to FDA on Distinguishable Naming

On August 14, the Biologics Prescribers Collaborative sent a letter to FDA Commissioner Hamburg advocating for distinguishable naming for biosimilars.  Read More ›

June 10, 2014

National Alliance for Hispanic Health Letter to FDA

On June 10, the National Alliance for Hispanic Health and twenty-two undersigned groups, representing millions of U.S. patients and professional caregivers involved in minority health, sent a letter to FDA urging for distinguishable names for biosimilars. Read More ›

June 3, 2014

NORD Letter to FDA on Distinguishable Naming

On June 3, the National Organization for Rare Disorders (NORD) sent a letter to FDA Commissioner Hamburg advocating for distinguishable naming for biosimilars.  Read More ›

May 20, 2014

Society for Women’s Health Research (SWHR) and patient advocates Letter to FDA

On May 20, SWHR and 45 patient advocacy groups sent a letter urging FDA to consider gender-based Disparities in medical research and treatment when establishing an approach to biosimilar naming. Read More ›